China Isotope & Radiation Corporation $(CIRC.UK)$ has announced a strategic cooperation agreement with Qianlong International Holdings Limited. The collaboration aims to promote and expand the application of boron neutron capture therapy technology (BNCT) and other nuclear medical innovations. This partnership will focus on establishing oncology treatment institutions in China, enhancing the use of nuclear medical equipment, radiopharmaceuticals, and intelligent nuclear medicine solutions both domestically and internationally. The agreement underscores a commitment to advancing nuclear medicine industries through technological innovation, benefiting public health on both sides of the strait. Qianlong International, based in Hong Kong, specializes in biotechnology and digital health investments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.